Envoys of 64 countries visit COVID vaccine makers in Hyderabad

HYDERABAD: Envoys of 64 countries on Wednesday visited the facilities of Bharat Biotech and Biological E, which are developing vaccines for coronavirus. After landing in Hyderabad by a special Air India flight, the Ambassadors and High Commissioners from the countries in Asia, Africa, Europe, North America, South America, and Oceania reached Genome Valley on the city outskirts to visit the two companies.

The visit by the heads of foreign missions was organised by the Ministry of External Affairs (MEA) and was part of India's efforts to develop partnerships for the manufacture and delivery of vaccines.

Officials said the diplomats were divided into two batches and they went around the two companies to see for themselves the facilities developed for research and manufacturing of vaccines. Top officials of both the companies briefed the envoys about the progress made so far in the development of the vaccines and the rollout plans by both the companies after their vaccines get the approval from regulators.

At Bharat Biotech, the delegation was briefed about company's vaccine development programme by Dr. Krishna Ella, Chairman and Managing Director, spearheading Covaxin research, development, clinical trials and production teams.

The delegates were explained about Bharat Biotech's research process, manufacturing capabilities, expertise through virtual and physical tours of the facilities. The envoys voiced their appreciation of the company's work of national and global public health significance.

Covaxin, India's indigenous COVID-19 vaccine, is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility.

Covaxin is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.

According to Bharat Biotech, Covaxin has been evaluated in approximately 1000 subjects in Phase 1 and Phase 2 clinical trials, with promising safety and immunogenicity results. The Phase 3 human clinical trials of the vaccine began in November, involving 26,000 volunteers across India. This is India's first and only Phase 3 efficacy study for a COVID-19 vaccine, and the largest phase 3 efficacy trial ever conducted for any vaccine in India.

Biological E last month initiated clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India (DGCI).

It is making the vaccine in collaboration with Dynavax Technologies Corporation (Dynavax), a US-based vaccine focused biopharmaceutical company, and Baylor College of Medicine, a health sciences university in Houston.

Telangana Chief Secretary Somesh Kumar also addressed the diplomats and showcased the potential of the state. He said though being the youngest state in the country, Teangana achieved tremendous progress under the dynamic leadership of Chief Minister K. Chandrasekhar Rao. He also informed that the combined value of the pharma sector in the state is around $50 billion. Hyderabad is the vaccine hub of not only India but the entire world with 33 percent of the entire vaccine production being done in Hyderabad. (IANS)

Also Read: Civil society group seeks transparency in COVID vaccine emergency approval

Also Watch: Poor infrastructure condition of Guwahati areas leave residents angry and upset